These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34809599)

  • 1. Survival impact of additional chemotherapy after adjuvant concurrent chemoradiation in patients with early cervical cancer who underwent radical hysterectomy.
    Kim SI; Kim JY; Wee CW; Lee M; Kim HS; Chung HH; Lee TS; Jeon HW; Park NH; Song YS; Kim TH
    BMC Cancer; 2021 Nov; 21(1):1260. PubMed ID: 34809599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant chemotherapy versus concurrent chemoradiotherapy for high-risk cervical cancer after radical hysterectomy and systematic lymphadenectomy.
    Takekuma M; Kasamatsu Y; Kado N; Kuji S; Tanaka A; Takahashi N; Abe M; Hirashima Y
    Int J Clin Oncol; 2016 Aug; 21(4):741-747. PubMed ID: 26857458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The long-term efficacy of neoadjuvant chemotherapy followed by radical hysterectomy compared with radical surgery alone or concurrent chemoradiotherapy on locally advanced-stage cervical cancer.
    Yin M; Zhao F; Lou G; Zhang H; Sun M; Li C; Hou Y; Li X; Meng F; Chen X
    Int J Gynecol Cancer; 2011 Jan; 21(1):92-9. PubMed ID: 21330834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Role of Adjuvant Chemotherapy after Radical Hysterectomy for FIGO Stage IB-IIA Cervical Cancer: Comparison with Adjuvant RT/CCRT Using Inverse-Probability-of-Treatment Weighting.
    Jung PS; Kim DY; Lee SW; Park JY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
    PLoS One; 2015; 10(7):e0132298. PubMed ID: 26176626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platinum-based combination chemotherapy vs. weekly cisplatin during adjuvant CCRT in early cervical cancer with pelvic LN metastasis.
    Lee YY; Park W; Huh SJ; Yoon A; Park JY; Choi CH; Kim TJ; Lee JW; Kim BG; Bae DS
    Anticancer Res; 2013 Oct; 33(10):4675-81. PubMed ID: 24123048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience.
    Okazawa M; Mabuchi S; Isohashi F; Suzuki O; Yoshioka Y; Sasano T; Ohta Y; Kamiura S; Ogawa K; Kimura T
    Int J Gynecol Cancer; 2013 Mar; 23(3):567-75. PubMed ID: 23385284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of adjuvant therapy for node-positive clinical stage IB-IIB cervical cancer: Systemic chemotherapy versus pelvic irradiation.
    Matsuo K; Shimada M; Aoki Y; Sakamoto M; Takeshima N; Fujiwara H; Matsumoto T; Mikami M; Sugiyama T
    Int J Cancer; 2017 Sep; 141(5):1042-1051. PubMed ID: 28524247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Results of different postoperative adjuvant therapies for stage Ib-IIa cervical carcinoma with risk factors].
    Wen HW; Huang WP; Liu TY; Ma K; Tao X; Zhu LR; Liao QP
    Zhonghua Fu Chan Ke Za Zhi; 2013 Dec; 48(12):920-4. PubMed ID: 24495686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.
    Kokka F; Bryant A; Brockbank E; Powell M; Oram D
    Cochrane Database Syst Rev; 2015 Apr; (4):CD010260. PubMed ID: 25847525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly versus triweekly cisplatin-alone adjuvant chemoradiotherapy after radical hysterectomy for stages IB-IIA cervical cancer with risk of recurrence.
    Zhu J; Lou R; Ji S; Wu G; Chen Q; Hu Q; Zhao Y; Cai D; Gu K
    Anticancer Drugs; 2021 Feb; 32(2):203-209. PubMed ID: 33186140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postoperative adjuvant concurrent chemoradiotherapy improves survival rates for high-risk, early stage cervical cancer patients.
    Ryu HS; Chun M; Chang KH; Chang HJ; Lee JP
    Gynecol Oncol; 2005 Feb; 96(2):490-5. PubMed ID: 15661240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of Prognostic Factors Affecting the Outcome of Stage IB-IIB Cervical Cancer Treated by Radical Hysterectomy and Pelvic Lymphadenectomy.
    Xia X; Xu H; Wang Z; Liu R; Hu T; Li S
    Am J Clin Oncol; 2016 Dec; 39(6):604-608. PubMed ID: 24937635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent paclitaxel/cisplatin chemoradiotherapy with or without consolidation chemotherapy in high-risk early-stage cervical cancer patients following radical hysterectomy: preliminary results of a phase III randomized study.
    Zhao H; Li L; Su H; Lin B; Zhang X; Xue S; Fei Z; Zhao L; Pan Q; Jin X; Xie C
    Oncotarget; 2016 Oct; 7(43):70969-70978. PubMed ID: 27391158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The upper limit of optimal tumor size in patients with FIGO 2018 stage IB2 cervical cancer undergoing radical hysterectomy.
    Hwang WY; Kim JH; Suh DH; Kim K; No JH; Kim YB
    Int J Gynecol Cancer; 2020 Jul; 30(7):975-980. PubMed ID: 32467336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Curative effect analysis of postoperative concurrent chemoradiotherapy on early-stage cervical cancer patients with intermediate-risk factors].
    Tang Q; Tu YQ; Chen JH; Lyu XJ; Yan DD
    Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):462-466. PubMed ID: 29936774
    [No Abstract]   [Full Text] [Related]  

  • 16. Adjuvant chemotherapy after concurrent chemoradiation for locally advanced cervical cancer.
    Tangjitgamol S; Katanyoo K; Laopaiboon M; Lumbiganon P; Manusirivithaya S; Supawattanabodee B
    Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010401. PubMed ID: 25470408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Definite chemoradiotherapy is a competent treatment option in FIGO stage IB2 cervical cancer compared with radical surgery +/- neoadjuvant chemotherapy.
    Hsieh HY; Huang JW; Lu CH; Lin JC; Wang L
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 1):99-108. PubMed ID: 29429800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of survival outcomes between minimally invasive surgery and conventional open surgery for radical hysterectomy as primary treatment in patients with stage IB1-IIA2 cervical cancer.
    Kim SI; Cho JH; Seol A; Kim YI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
    Gynecol Oncol; 2019 Apr; 153(1):3-12. PubMed ID: 30642625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Neoadjuvant Chemotherapy Plus Radical Surgery as Front Line Treatment Strategy in Patients Affected by FIGO Stage III Cervical Cancer.
    Di Donato V; Schiavi MC; Ruscito I; Visentin VS; Palaia I; Marchetti C; Fischetti M; Monti M; Muzii L; Benedetti Panici P
    Ann Surg Oncol; 2016 Dec; 23(Suppl 5):841-849. PubMed ID: 27678502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of adjuvant therapy after radical hysterectomy in intermediate-risk, early-stage cervical cancer.
    Cao L; Wen H; Feng Z; Han X; Zhu J; Wu X
    Int J Gynecol Cancer; 2021 Jan; 31(1):52-58. PubMed ID: 33303568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.